Role of adaptive radiotherapy during concomitant chemoradiotherapy for limited-stage small-cell lung cancer.
| Autor: | Ozdemir BS; Department of Radiation Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey., Yavuz AA |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Indian journal of cancer [Indian J Cancer] 2024 Jul 13. Date of Electronic Publication: 2024 Jul 13. |
| DOI: | 10.4103/ijc.IJC_578_20 |
| Abstrakt: | Background: Tumor shrinkage is frequently observed during conventionally fractionated chemoradiotherapy for limited-stage small-cell lung cancer (SCLC). The specific goals of this study are to evaluate the gross tumor volume (GTV) changes due to treatment-induced tumor reduction during the course of radiotherapy (RT) and to examine its potential use in adaptive radiotherapy (ART) for tumor dose escalation or normal tissue sparing in patients with SCLC. Materials and Methods: A total of 10 patients with SCLC eligible for chemoradiotherapy underwent computed tomography (CT) scan after Fractions 13 and 23 (at nominal doses of 23.4 Gy and 41.4 Gy, respectively). The GTV was delineated on the repeat CT scans, and two treatment plans were generated with or without adaptation to tumor shrinkage during RT for each patient. Dosimetric and volumetric analyses were performed. Results: The average GTV reduction observed over 13 fractions was 58.5% (range: 13.2%-92.3%; P < 0.001) and over 23 fractions was 70% (range: 36.9%-84.5%; P < 0.001). Compared with the plan without adaptation, ART resulted in mean lung dose relative decreases of 8.7%, mean lung volume receiving ≥20 Gy relative decreases of 5%, mean lung volume receiving ≥5Gy relative decreases of 10%, mean medulla spinalis dose relative decreases of 21 cGy, mean esophagus volume receiving ≥50 Gy relative decreases of 19%, and mean heart volume receiving ≥42 Gy relative decreases of 13%. The benefits of ART were the greatest for tumor volumes ≥30 cm 3 and are directly dependent on GTV reduction during treatment. Conclusion: ART for SCLC achieved a significant benefit in terms of organ at risk (OAR) and dose escalation. (Copyright © 2024 Copyright: © 2024 Indian Journal of Cancer.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|